In a notable portfolio shift, life sciences investment firm Casdin Capital fully exited its position in Tempus AI (TEM) during the second quarter of 2026. The firm sold all 294,130 of its shares, which had been valued at approximately $13.30 million at the end of the prior quarter. At that time, the stake in the artificial intelligence and precision medicine company represented just over 1% of Casdin Capital's reported public holdings.
This trade information comes from a quarterly 13F filing submitted to the SEC on August 14, 2026. Investors should note that these filings reflect a fund's holdings as of a specific past date—in this case, June 30, 2026—and do not necessarily represent the firm's current portfolio. The transaction could have occurred any time between April 1 and the end of June. Casdin Capital is known for its focused investments in innovative healthcare and biotechnology companies.